Feed ANIP
AN

ANI Pharmaceuticals, Inc. ANIP · NASDAQ

$72.67 +0.15% (+$0.11)

Market cap
$1.67B
Enterprise value
$1.64B
P/E
15.7x
Forward P/E
8.5x
PEG
-
P/S
1.7x
P/FCF
10.4x
EV/EBITDA
6.4x
ROIC
9.3%
Gross margin
65.2%
Net margin
10.8%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-0.1x
Beta
0.50
Free float
85.7%

About the company

ANI Pharmaceuticals, Inc. (ANI) is an American pharmaceutical company specializing in the development, manufacturing, and sale of generic and specialty pharmaceuticals. With a broad portfolio of pharmaceutical products, including generic versions of drug substances and specialty drugs for various therapeutic indications, ANI Pharmaceuticals is a recognized player in the pharmaceutical market. The company focuses on providing affordable and quality medicines for patients and healthcare facilities across the United States. ANI Pharmaceuticals also invests in research and development of new pharmaceutical products and seeks opportunities to expand its portfolio through acquisitions and licenses. ANI Pharmaceuticals, Inc. (ANI) shares could be suitable for investors seeking investment opportunities in the pharmaceutical industry and generic drugs.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Nikhil Lalwani

Employees

970

Headquarters

Baudette

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.